BeiGene (FRA:49BA) Short-Term Capital Lease Obligation : €20 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene Short-Term Capital Lease Obligation?

BeiGene's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €20 Mil.

BeiGene's quarterly Short-Term Capital Lease Obligation increased from Jun. 2023 (€22 Mil) to Sep. 2023 (€22 Mil) but then declined from Sep. 2023 (€22 Mil) to Dec. 2023 (€20 Mil).

BeiGene's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€19 Mil) to Dec. 2022 (€23 Mil) but then declined from Dec. 2022 (€23 Mil) to Dec. 2023 (€20 Mil).

BeiGene Short-Term Capital Lease Obligation Historical Data

The historical data trend for BeiGene's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Short-Term Capital Lease Obligation Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

9.73

11.42

19.40

22.70

20.13

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															22.70	22.93	21.70	21.78	20.13

BeiGene Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

BeiGene Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of BeiGene's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines